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Abstract 
Background: There is uncertainty regarding how stable complement analytes are during long-term storage at – 80 °C. 
As part of our work program we have measured 17 complement biomarkers (C1q, C1 inhibitor, C3, C3a, iC3b, C4, C5, C9, 
FB, FD, FH, FI, TCC, Bb, sCR1, sCR2, Clusterin) and the benchmark inflammatory marker C-reactive protein (CRP) in a large 
set of plasma samples (n = 720) that had been collected, processed and subsequently stored at – 80 °C over a period 
of 6.6–10.6 years, prior to laboratory analysis. The biomarkers were measured using solid-phase enzyme immunoas-
says with a combination of multiplex assays using the MesoScale Discovery Platform and single-plex enzyme-linked 
immunosorbent assays (ELISAs). As part of a post hoc analysis of extrinsic factors (co-variables) affecting the analyses 
we investigated the impact of freezer storage time on the values obtained for each complement analyte.
Results: With the exception of five analytes (C4, C9, sCR2, clusterin and CRP), storage time was significantly correlated 
with measured plasma concentrations. For ten analytes: C3, FI, FB, FD, C5, sCR1, C3a, iC3b, Bb and TCC, storage time 
was positively correlated with concentration and for three analytes: FH, C1q, and C1 inhibitor, storage time was nega-
tively correlated with concentration.
Conclusions: The results suggest that information on storage time should be regarded as an important co-variable 
and taken into consideration when analysing data to look for associations of complement biomarker levels and dis-
ease or other outcomes.
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Background
Complement is an important part of innate immunity 
and plays a key role in inflammatory processes. The com-
plement pathway includes more than 30 component pro-
teins, regulators and receptors, which work together to 
fight infection and to clear toxic material. Concentrations 
of complement biomarkers in plasma have been found to 
be altered in a wide range of different diseases, includ-
ing cancer, atherosclerosis, diabetes, inflammatory bowel 
disease, neurodegenerative disorders, autoimmune dis-
eases and infections [1].
Levels of complement biomarkers are often inconsist-
ent between different laboratories due in part to a lack 
of standardisation with variation occurring in sample 
collection, handling and storage [2–4]. As part of our 
work program assessing biomarkers in dementia, we have 
measured 17 complement biomarkers (C1q, C1 inhibitor 
(C1inh), C3, C3a, iC3b, C4, C5, C9, FB, FD, FH, FI, TCC, 
Bb, sCR1, sCR2, clusterin) and the benchmark inflam-
matory marker C-reactive protein (CRP) in a large set of 
plasma samples (n = 720) that had been collected, pro-
cessed and subsequently stored at – 80 °C over a period 
of 4  years. Before investigating any possible association 
with dementia the biomarker levels were assessed for 
relationships with relevant co-variables that could influ-
ence the main results. Here we report our investigation 
of the impact of the freezer storage time on the measure-
ment of complement biomarkers.
Methods
Samples
Samples were from the AddNeuroMed study, a cross-
European cohort for biomarker discovery. Informed 
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consent was obtained for all subjects according to the 
Declaration of Helsinki (1991) and protocols and proce-
dures were approved by the relevant Institutional Review 
Board at each collection site. Further information regard-
ing the cohort has been previously described [5, 6]. This 
study utilised plasma samples from 720 subjects: 262 
with Alzheimer’s disease, 199 with mild cognitive impair-
ment, and 259 elderly controls with no dementia.
Plasma samples were collected into clinical grade 
EDTA tubes  (K2EDTA; final concentration 1.8  g/l) and 
centrifuged at 3000  rpm for 8  min at 4  °C. Plasma was 
harvested, aliquoted and then frozen at – 80 °C.
Measuring the levels of clusterin, soluble complement 
receptor 2 and CRP
The plasma levels of clusterin, soluble complement 
receptor 2 (sCR2) and CRP were determined using com-
mercially available enzyme-linked immunosorbent assay 
(ELISA)—compatible antibody pairs (clusterin and CRP 
from R&D systems (Abingdon, UK) (cat# DY5874 and 
DY1707) and sCR2 from Sino Biological (Beijing, China) 
(cat# SEKA10811)) and protocols were followed as 
described by the manufacturers.
Measuring the levels of soluble complement receptor 1, 
C1‑inhibitor, C5, C9 and C1q
The plasma levels of soluble complement receptor 1 
(sCR1), C1-inhibitor (C1inh), C5, C9 and C1q were 
determined using optimised antibody pairs in sandwich 
ELISAs developed in-house. See Table  1 for details of 
each assay. Further information regarding our in house 
ELISA methods has been previously described [7].
Measuring the levels of C3, C4, factor B, factor H, factor I, 
factor D, Bb, C3a, iC3b, and terminal complement complex
The majority of the complement proteins in this study 
were measured using customised v-plex assays from 
MesoScale Discovery (MSD; Rockville, Maryland, 
USA), using antibody pairs developed in-house. C3, 
C4, factor B (FB), factor H (FH) and factor I (FI) were 
analysed together in multiplex 1 and factor D (FD), Bb, 
C3a, iC3b and terminal complement complex (TCC) 
were analysed together in multiplex 2. All 8 analytes 
were measured by an electrochemiluminescence (ECL) 
immunoassay technique according to the manufactur-
er’s protocol. In brief, pre-coated plates were blocked 
with 150  μl/well 3% BSA in PBS at room temperature 
for 2  h with shaking at 600  rpm. Plasma samples were 
diluted 1:2000 for multiplex 1 and 1:2 for multiplex 
2 in assay buffer (PBS containing 1% BSA and 10  mM 
EDTA) and 25  μl aliquots were added in duplicate to 
wells. A calibration curve comprising a series of five-
fold dilutions of protein standard was run in duplicate 
on each plate. Plates were incubated with shaking at 
600  rpm at room temperature for 60  min. After wash-
ing in PBS containing 0.01% Tween20, 25  μl of a mix-
ture of the relevant SULFO-TAG-labelled detection 
antibodies diluted in assay buffer (1:100) was added and 
incubated with shaking at 600 rpm at room temperature 
for 60 min. After washing, 150 μl of 2 × MSD reading 
buffer was added to each well and ECL signal was meas-
ured on the Sector Imager 2400 (MSD).
Qc
All standards and samples for all assays were tested in 
duplicate. The intra-assay and inter-assay coefficients of 
variation (CV) % were set at 25% and data for any sample 
with a CV above this was not included.
Statistical analysis
Protein concentrations were determined automatically 
from standard curves plotted using GraphPadPrism5. 
The units of concentration for all analytes shown are 
nanogram per milliliter. Spearman correlation tests were 
used in GraphPadPrism5 to identify correlations between 
protein levels and time in freezer.
Table 1 In-house ELISAs
MM mouse monoclonal antibody, RP rabbit polyclonal antibody
Analyte Capture antibody Detection antibody Standard curve Plasma dilution
sCR1 1 µg/ml RP anti-CR1 1 µg/ml MM HRP labelled anti-human 
CR1
50, 25, 12.5, 6.25, 3.125, 1.565, 0.78, 
0 ng/ml
1:2
C5 1 µg/ml RP anti-C5 1 µg/ml MM HRP labelled anti-human 
C5
1000, 500, 250, 125, 62.5, 31.25, 
15.625, 0 ng/ml
1:100
C9 1 µg/ml MM anti-C9 1 µg/ml RP HRP labelled anti-human 
C9
100, 50, 25, 12.5, 6.25, 3.125, 1.5625, 
0 ng/ml
1:2000
C1q 2 µg/ml MM anti-C1q (commercial 
WL02 from Hycult)
1 µg/ml RP HRP labelled anti-human 
C1q
1000, 500, 250, 125, 62.5, 31.25, 
15.625, 0 ng/ml
1:800
C1 inhibitor 1 µg/ml MM anti-C1 inhibitor 1 µg/ml RP HRP labelled anti-human 
C1 inhibitor
100, 50, 25, 12.5, 6.25, 3.125, 1.5625, 
0 ng/ml
1:16,000
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Results
The concentrations of 18 complement biomarkers were 
measured in 720 plasma samples by solid-phase enzyme 
immunoassays. The means, ranges and standard devia-
tions for each analyte are shown in Table  2. Results 
obtained are compatible with published values for these 
analytes, taking into account that this is a cohort of 
elderly individuals, many with significant pathology. A 
number of co-variables were considered in the analy-
sis of the data, including length of storage of samples 
at – 80 °C. The time the samples had been stored in the 
freezer before the measurement of biomarkers ranged 
from 6.6 to 10.6  years (mean 9.1. SD 0.6). The samples 
had not undergone any previous freeze–thaws and were 
transferred from the collection centres frozen on dry ice.
The cohort was tested for correlations between indi-
vidual biomarker levels and time in freezer (Table 3 and 
Additional file  1). With the exception of five analytes 
(C4, C9, sCR2, clusterin and CRP), storage time was sig-
nificantly correlated with measured plasma value. For 
ten analytes: C3, FI, FB, FD, C5, sCR1, C3a, iC3b, Bb and 
TCC, storage time was positively correlated, samples 
yielding significantly higher concentrations with longer 
time in the freezer. Using a linear model it was deter-
mined that concentration was increased for each year a 
sample was stored in the freezer by 30.3% (304,216  ng/
ml) for C3, 8.1% (2808 ng/ml) for FI, 5.2% (5413 ng/ml) 
for FB, 5.8% (123  ng/ml) for FD, 5.4% (1418  ng/ml) for 
C5, 4.4% (0.53 ng/ml) for sCR1, 12.1% (13 ng/ml) for C3a, 
9.7% (23 ng/ml) for iC3b, 6.1% (8 ng/ml) for Bb and 12.3% 
(16 ng/ml) for TCC. The storage time was negatively cor-
related with three of the proteins: FH, C1q, and C1inh 
which all displayed statistically significant lower con-
centrations with longer time in the freezer. Using a lin-
ear model it was determined that concentration decrease 
for each year a sample was stored in the freezer was 4.5% 
(11,452 ng/ml) for FH, 7.5% (13,285 ng/ml) for C1q and 
2.8% (6710 for ng/ml) for C1inh.
Discussion
Many plasma samples are stored for a number of years 
in the freezer before their use in biomarker studies and 
there are questions regarding how stable complement 
analytes are during long-term storage at – 80 °C. As part 
of our work program we had measured a large panel of 
complement biomarker analytes in a relatively large 
plasma set that had been stored at – 80  °C for between 
6.6 and 10.6  years. As part of a post hoc analysis of 
extrinsic factors (co-variables) affecting the analyses we 
investigated the impact of freezer storage time on the 
values obtained for each complement analyte. Of the 18 
analytes measured, ten had increased levels with longer 
time of storage at −  80  °C, three had decreased levels 
and five were not significantly changed. Notably, all four 
of the complement activation products (C3a, iC3b, Bb, 
TCC) included in the analysis were strongly positively 
correlated with storage time—all increased significantly 
in measured level. This suggests that there is significant 
“activation” of complement in EDTA plasma on long-
term storage even at − 80 °C.
The study we report here is not without its limitations, 
the main one being that only one sample per subject was 
available. The best approach may be to measure samples 
at the time of collection and periodically thereafter using 
aliquots of the same samples on the same assay platform. 
However, such an experimental set-up is logistically dif-
ficult and even this is not without its own limitations as 
when comparing measurements taken at different times 
it is difficult to control for the variability this introduces. 
Measurements taken years later will be taken with dif-
ferent reagent batches and more than likely by different 
personnel.
There are few reports on the impact of storage time on 
levels of individual complement analytes and with only 
very small sample sets. Mollnes and co-workers made 
a pool of EDTA plasma obtained from 40 healthy blood 
donors; they stored the plasma for 3  years at −  70  °C, 
and compared with a similar fresh pool. When exam-
ined together, these two pools showed exactly the same 
amount of C3 activation products (15 AU/ml) and TCC 
(5 AU/ml) [2]. In another study of storage of 88 plasma 
samples at − 80 °C for 0–6 years, no significant effect of 
length of storage time was found on levels of complement 
Table 2 Means and range of protein levels (ng/ml)
Analyte n Min Max Mean SD
C3 690 235,097 8423,462 1004,059 528,689
FI 701 7419 69,773 34,876 8314
FB 695 27,419 295,598 103,430 28,238
FD 719 1092 4695 2125 607
C5 720 13,405 47,415 26,369 5458
sCR1 715 4 38 12 4
C3a 703 38 339 109 46
iC3b 571 38 726 240 133
Bb 719 50 1325 128 81
TCC 717 32 2941 132 252
FH 674 69,782 630,889 252,816 72,781
C1q 720 33,250 363,624 177,275 44,275
C1 inhibitor 719 81,192 673,570 236,527 59,156
C4 702 32,722 719,480 174,190 78,337
C9 719 23,542 268,083 81,610 29,727
sCR2 712 46 625 175 70
Clusterin 720 112,694 532,722 226,729 42,704
CRP 702 70 11,864 1255 1422
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activation products C3a, C4d, C5a, TCC (C5b-9 in this 
study) and Bb [8]. Our samples had been stored for 
longer than those in the described studies and this might 
explain in part the differences between our observations 
and those in these published studies. More likely is that 
in our study, the power provided by the large sample set 
(720 samples), and number of analytes, reveals storage 
effects not apparent in the published smaller studies.
There are further reports on the impact of storage time 
on non-complement biomarkers. One study reported 
that a 4-year difference in long-term storage had minimal 
effect on protein in plasma [9] while three other studies 
did report changes in protein biomarker levels with stor-
age time. One study performed a time course analysis 
of cytokines, chemokines and growth factors measured 
in the banked serum of healthy donors and melanoma 
patients stored for various intervals, and analysed by 
multiplex Luminex assays. Seven of the ten analytes 
examined showed highly significant changes during the 
approximately 5 years of storage at − 80 °C [10]. Enroth 
and co-workers found that plasma values of 18 of 108 
protein biomarkers investigated were influenced by stor-
age time (storage time 2–28  years) [11], while Kugler 
et  al. found that levels of two serum markers measured 
at sample collection and again in the same samples after 
approximately 10 years in storage increased by 15% [12]. 
Taken together, these findings demonstrate that storage 
time needs to be a consideration in all biomarker studies 
using stored plasma samples, not just those focussing on 
complement.
If the effects of storage can be modelled then it may 
be possible to introduce a correction factor for time of 
storage that “normalises” the data and permits the use of 
samples stored for different times without compromising 
a study. When analysing our own data further we plan to 
adjust the complement concentrations observed based 
on linear models and estimate the concentration of each 
sample based on a time in freezer measure of 9  years, 
chosen because it represents the mean time of storage in 
the study, thus minimising the applied adjustment.
Conclusions
The key finding of this study is that long-term storage of 
plasma even at − 80 °C alters levels of some complement 
components and all complement activation products. 
These effects must be taken into consideration when 
analysing data from historical sample sets spanning long 
periods of storage time, the case in most biobanks and 
other archived collections. Information on storage time 
must be regarded as an important co-variable, just as 
important as patient age or gender, and taken into con-
sideration (and corrected for) when analysing data to 
look for associations of complement biomarker levels and 
disease or other outcomes.
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